XORTX Therapeutics’ three-month net loss narrows 41% to USD 382,100
XRTX•XORTX Therapeutics’ net loss narrowed 41% year over year to USD 382,100 for the three months ended September 30, 2026. Cash was USD 318,846 at quarter-end, down 63% from December 31, 2025.
1. Quarterly results
XORTX Therapeutics reported a net loss of USD 382,100 for the three months ended September 30, 2026, a 41% year-over-year decrease. Operating cash outflow more than doubled year over year to USD 4.34 million for the nine months ended September 30, while cash fell 63% from December 31, 2025, to USD 318,846.
2. Program acquisition
The company’s acquisition of Vectus Biosystems’ VB4-P5 renal anti-fibrotic therapeutic program closed April 13, 2026, at a total cost of USD 2.34 million.




